Related Experiment Video
Updated: Jun 26, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Heterogeneity Analyzed by CT-Based Habitat Analysis for Clinical Management of Cancers: A Narrative Review
Yang Zhang1,2, Zhi-Yan Jin2, Min-Ying Lydia Su1,3
1Department of Radiological Sciences, University of California, Irvine, California, USA.
None:
Tumors are highly heterogeneous, and whole-lesion radiomics analysis is a popular method for extracting texture features that reflect this heterogeneity, which can be used to build models for cancer diagnosis, staging, therapy response evaluation, and prognosis prediction. However, there is no spatial information for understanding which components provide the most critical information. Recently, habitat analysis has gained widespread attention, and it is used to divide a tumor into distinct sub-regions, called habitats, that share common characteristics. CT reveals heterogeneity in attenuation, texture, entropy, and enhancement patterns, which can be used to generate habitats. In the past 2 years, many studies exploring the role of CT habitats have been reported. The divided habitats can be used to build models for the classification of histological or molecular subtypes, the evaluation and prediction of treatment response, and prognostication of progression-free survival or overall survival. This review aims to summarize studies on the application of CT-habitat analysis for cancer management. In addition to clinical applications, various methods for habitat segmentation will be reviewed. Lastly, how spatial information revealed by the habitat can guide tissue biopsy for tissue-level confirmation studies will be described, which is critical for understanding the underlying biology and paving the way for future clinical implementation.
Related Concept Videos
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Hazard Ratio
For example, in a clinical trial evaluating a...
